<DOC>
	<DOC>NCT01830595</DOC>
	<brief_summary>Our general goal is to evaluate the potential effectiveness of recombinant lactoferrin (1500mg bid) for reducing inflammation among HIV positive participants.</brief_summary>
	<brief_title>Lactoferrin Treatment in HIV Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lactoferrin</mesh_term>
	<criteria>1. HIVpositive participants receiving ART for &gt;1 year 2. HIV RNA level &lt;200 copies/mL for at least 6 months (â‰¥2 separate values) 3. Age &gt;40 years 1. Prior cardiovascular disease or stroke 2. Diabetes 3. Rheumatologic Diseases 4. Pregnancy 5. Chronic kidney disease, stage IV or V (creatinine clearance &lt;30 mL/min/1.73m2) 6. Cirrhosis or endstage liver disease</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>